Aquapass Fluid Overload Management System Gains Marketing Approval in Israel

Aquapass System Approved in Israel for Fluid Overload Treatment

December 12, 2025—Aquapass, developer of noninvasive, kidney-independent solutions for fluid overload management in patients experiencing heart failure and chronic or end-stage kidney disease, announced marketing approval in Israel for the Aquapass system for the treatment of patients with fluid overload. The company noted that with the approval, Aquapass transitions into a commercial-phase company and establishes the foundation for its internat…

Aquapass fluid overload management system gains marketing approval in Israel

Aquapass has received Israeli marketing approval for its non-invasive system for fluid overload management in patients suffering from heart failure and chronic or end-stage kidney disease. As part of the initial rollout, Aquapass will begin commercial deployment in selected medical centres across Israel, working with clinicians to collect clinical feedback and develop real-world evidence that will support broader adoption and long-term integrati…